TW200837080A - Anti-IL-13 antibody formulations and uses thereof - Google Patents

Anti-IL-13 antibody formulations and uses thereof Download PDF

Info

Publication number
TW200837080A
TW200837080A TW097100809A TW97100809A TW200837080A TW 200837080 A TW200837080 A TW 200837080A TW 097100809 A TW097100809 A TW 097100809A TW 97100809 A TW97100809 A TW 97100809A TW 200837080 A TW200837080 A TW 200837080A
Authority
TW
Taiwan
Prior art keywords
formulation
antibody
months
buffer
species
Prior art date
Application number
TW097100809A
Other languages
English (en)
Chinese (zh)
Inventor
Anthony B Barry
Thomas J Crowley
Daniel A Dixon
Erin Christine Soley
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of TW200837080A publication Critical patent/TW200837080A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/544—Mucosal route to the airways
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Otolaryngology (AREA)
  • Mycology (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW097100809A 2007-01-09 2008-01-09 Anti-IL-13 antibody formulations and uses thereof TW200837080A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87950007P 2007-01-09 2007-01-09

Publications (1)

Publication Number Publication Date
TW200837080A true TW200837080A (en) 2008-09-16

Family

ID=39609351

Family Applications (1)

Application Number Title Priority Date Filing Date
TW097100809A TW200837080A (en) 2007-01-09 2008-01-09 Anti-IL-13 antibody formulations and uses thereof

Country Status (13)

Country Link
US (1) US20090060906A1 (enExample)
EP (1) EP2114451A2 (enExample)
JP (1) JP5419709B2 (enExample)
CN (1) CN101600457B (enExample)
AR (1) AR064826A1 (enExample)
AU (1) AU2008204901A1 (enExample)
BR (1) BRPI0806313A2 (enExample)
CA (1) CA2674608A1 (enExample)
CL (1) CL2008000058A1 (enExample)
MX (1) MX2009007406A (enExample)
PE (1) PE20081610A1 (enExample)
TW (1) TW200837080A (enExample)
WO (1) WO2008086395A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI476004B (zh) * 2009-03-11 2015-03-11 優稀美製藥股份有限公司 對人類ｉｌ－１３具結合專一性的抗體分子

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
ES2614274T3 (es) * 2002-09-06 2017-05-30 Alexion Pharmaceuticals, Inc. Procedimiento de tratamiento de asma usando anticuerpos frente al componente de complemento C5
US9415102B2 (en) 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
AU2004229335C1 (en) 2003-04-04 2010-06-17 Genentech, Inc. High concentration antibody and protein formulations
US7736644B2 (en) 2003-06-27 2010-06-15 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
WO2008057459A2 (en) 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonists of pcsk9
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
AR070315A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
AR070316A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
NZ587632A (en) 2008-03-14 2012-06-29 Biocon Ltd An anti-cd6 monoclonal antibody and a method thereof
RU2011101969A (ru) 2008-06-30 2012-08-10 Ново Нордиск А/С (DK) Антитела к человеческому интерлейкину-20
CA2749200A1 (en) * 2009-01-29 2010-08-05 Michael Bowen Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases
BRPI1006519A2 (pt) * 2009-03-06 2016-08-09 Genentech Inc formulação de anticorpos
ES2615881T3 (es) 2009-05-07 2017-06-08 Stallergenes Uso de inmunoglobulinas igg1 y/o de ligandos del receptor cd32 para el tratamiento de enfermedades y manifestaciones inflamatorias por vía mucosa.
US8454956B2 (en) 2009-08-31 2013-06-04 National Cheng Kung University Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies
BR112012012080B1 (pt) * 2009-11-20 2022-11-29 Biocon Limited Formulações de histidina-trealose do anticorpo t1h
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
ES2738114T3 (es) * 2010-02-11 2020-01-20 Ablynx Nv Métodos y composiciones para la preparación de aerosoles
EP3409289B1 (en) * 2010-02-26 2020-09-30 Novo Nordisk A/S Stable antibody containing compositions
RU2588658C2 (ru) 2010-04-27 2016-07-10 ЭсСиАйЭл Текнолоджи ГмбХ Стабильные водные композиции белка mia/cd-rap
RU2012153786A (ru) * 2010-05-28 2014-07-10 Ново Нордиск А/С Стабильные многодозовые композиции, содержащие антитело и консервант
SG190006A1 (en) 2010-11-04 2013-06-28 Boehringer Ingelheim Int Anti-il-23 antibodies
EP2652498B1 (en) 2010-12-16 2018-04-18 F.Hoffmann-La Roche Ag Diagnosis and treatments relating to th2 inhibition
TWI719112B (zh) 2011-03-16 2021-02-21 賽諾菲公司 雙重ｖ區類抗體蛋白質之用途
MX341076B (es) * 2011-03-31 2016-08-04 Merck Sharp & Dohme Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
UY34105A (es) * 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
RU2640025C2 (ru) * 2011-07-13 2017-12-25 Эббви Инк. Способы и композиции для лечения астмы с использованием антител против il-13
WO2013012022A1 (ja) 2011-07-19 2013-01-24 中外製薬株式会社 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
AR088579A1 (es) 2011-10-31 2014-06-18 Genentech Inc Formulaciones de anticuerpos
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
CN104507497B (zh) * 2012-05-03 2018-10-19 勃林格殷格翰国际有限公司 抗IL-23p19抗体
MX2014014717A (es) * 2012-06-21 2015-03-06 Ucb Pharma Sa Formulacion farmaceutica.
US9221904B2 (en) 2012-07-19 2015-12-29 National Cheng Kung University Treatment of osteoarthritis using IL-20 antagonists
US8852588B2 (en) 2012-08-07 2014-10-07 National Cheng Kung University Treating allergic airway disorders using anti-IL-20 receptor antibodies
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
TWI679019B (zh) * 2013-04-29 2019-12-11 法商賽諾菲公司 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
KR102405247B1 (ko) 2013-07-23 2022-06-07 바이오콘 리미티드 Cd6 결합 파트너의 용도 및 이에 기초한 방법
WO2015035342A2 (en) 2013-09-08 2015-03-12 Oligasis Llc Factor viii zwitterionic polymer conjugates
RU2016107435A (ru) 2013-09-13 2017-10-18 Дженентек, Инк. Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты
EP3683232A1 (en) 2013-09-13 2020-07-22 F. Hoffmann-La Roche AG Methods and compositions comprising purified recombinant polypeptides
BR112016008694A2 (pt) 2013-10-23 2017-10-03 Genentech Inc Métodos de previsão da reação de pacientes com asma, de previsão da capacidade de reação de pacientes com asma, de identificação de pacientes com asma, de tratamento de pacientes portadores de asma e de tratamento de asma, uso de um kit e kit
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9023359B1 (en) 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9051378B1 (en) 2014-07-15 2015-06-09 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US9045548B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
IL310015B2 (en) 2013-12-31 2026-02-01 Access To Advanced Health Inst Single vial formulation
UA117608C2 (uk) 2014-02-21 2018-08-27 Дженентек, Інк. Спосіб лікування еозинофільного захворювання у пацієнта шляхом застосування біспецифічного анти-il-13/il-17 антитіла
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US9150660B1 (en) 2014-07-15 2015-10-06 Kymab Limited Precision Medicine by targeting human NAV1.8 variants for treatment of pain
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
WO2016014775A1 (en) 2014-07-24 2016-01-28 Boehringer Ingelheim International Gmbh Biomarkers useful in the treatment of il-23a related diseases
AR101753A1 (es) 2014-09-03 2017-01-11 Boehringer Ingelheim Int COMPUESTO DE OBJETIVO A IL-23A Y TNF-a Y USO DEL MISMO
KR20210013299A (ko) 2014-10-17 2021-02-03 코디악 사이언시스 인코포레이티드 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
CA3093383A1 (en) 2014-10-24 2016-04-28 Merck Sharp & Dohme Corp. Co-agonists of the glucagon and glp-1 receptors
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
US20180000932A1 (en) * 2014-12-31 2018-01-04 Novelmed Therapeutics, Inc. Formulation of aglycosylated therapeutic antibodies
SG10202103879YA (en) 2015-02-04 2021-05-28 Boehringer Ingelheim Int Methods of treating inflammatory diseases
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
AU2016233398A1 (en) 2015-03-16 2017-09-07 F. Hoffmann-La Roche Ag Methods of detecting and quantifying IL-13 and uses in diagnosing and treating Th2-associated diseases
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
KR101808234B1 (ko) 2015-06-23 2017-12-12 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제
EP3383435A4 (en) * 2015-11-30 2019-07-10 Medimmune, LLC OPTIMIZED RATES OF AMINO ACIDS AND SUGARS AS AMORPHOUS STABILIZING COMPOUNDS IN PHARMACEUTICAL COMPOSITIONS HAVING HIGH CONCENTRATIONS IN PROTEIN-BASED THERAPEUTICS
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
KR20240052871A (ko) 2016-04-27 2024-04-23 애브비 인코포레이티드 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
HUE063135T2 (hu) 2016-09-23 2023-12-28 Hoffmann La Roche IL-13 antagonisták alkalmazásai atópiás dermatitis kezelésére
PL3529274T3 (pl) 2016-10-21 2024-09-09 Biocon Limited Przeciwciało monoklonalne i sposób jego stosowania w leczeniu tocznia
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
TWI716668B (zh) 2017-02-01 2021-01-21 耶魯大學 心臟衰竭及心腎症候群之精準治療
BR112019018022A2 (pt) * 2017-03-01 2020-06-02 Medimmune Limited Formulações de anticorpos monoclonais
AU2018250695A1 (en) 2017-04-14 2019-11-07 Kodiak Sciences Inc. Complement factor D antagonist antibodies and conjugates thereof
WO2018200533A1 (en) 2017-04-28 2018-11-01 Amgen Inc. Excipients to reduce the viscosity of antibody formulations and formulation compositions
RU2019138507A (ru) 2017-05-02 2021-06-02 Мерк Шарп И Доум Корп. Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
PL3639845T3 (pl) * 2017-07-25 2023-10-23 Jiangsu Hengrui Medicine Co., Ltd. Kompozycja farmaceutyczna zawierająca kompleks białka il-15 i jej zastosowania
AU2018321335B2 (en) * 2017-08-22 2025-08-14 Biogen Ma Inc. Pharmaceutical compositions containing anti-beta amyloid antibodies
AU2018322475A1 (en) * 2017-08-22 2020-03-05 Biogen Ma Inc. Pharmaceutical compositions and dosage regimens containing anti-alpha(v)beta(6) antibodies
MX2020006882A (es) 2018-01-05 2020-09-07 Novo Nordisk As Metodos para tratar inflamacion mediada por interleucina-6 sin inmunosupresion.
KR20230142806A (ko) 2018-02-09 2023-10-11 제넨테크, 인크. 비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법
US12071476B2 (en) 2018-03-02 2024-08-27 Kodiak Sciences Inc. IL-6 antibodies and fusion constructs and conjugates thereof
WO2019236435A1 (en) * 2018-06-07 2019-12-12 Merck Sharp & Dohme Corp. Lyosphere critical reagent kit
TW202011995A (zh) * 2018-07-03 2020-04-01 比利時商葛萊伯格有限公司 高濃度液體抗體配製物
CN113056482A (zh) 2018-10-18 2021-06-29 默沙东公司 抗rsv抗体的制剂及其使用方法
CN120842406A (zh) 2018-10-31 2025-10-28 默沙东有限责任公司 抗人pd-1抗体晶体及其使用方法
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
KR20210089215A (ko) 2018-11-07 2021-07-15 머크 샤프 앤드 돔 코포레이션 항-lag3 항체 및 항-pd-1 항체의 공동-제제
SG11202108627SA (en) 2019-02-18 2021-09-29 Lilly Co Eli Therapeutic antibody formulation
CN109771398B (zh) * 2019-02-25 2019-09-20 广州南鑫药业有限公司 一种帕拉米韦溶液型吸入剂及其制备方法
AU2020334880A1 (en) * 2019-08-16 2022-03-24 Regeneron Pharmaceuticals, Inc. High concentration anti-C5 formulations
TW202123965A (zh) 2019-09-09 2021-07-01 德商百靈佳殷格翰國際股份有限公司 抗-il-23p19抗體調配物
AU2020364071A1 (en) 2019-10-10 2022-05-26 Kodiak Sciences Inc. Methods of treating an eye disorder
US20230043290A1 (en) * 2019-12-20 2023-02-09 Ares Trading S.A. Igg:tgfbetarii fusion protein composition
CN115397394A (zh) * 2020-01-31 2022-11-25 赛诺菲 抗体的肺部递送
CA3169827A1 (en) * 2020-03-10 2021-09-16 Kunwar Shailubhai Compositions of il-6/il-6r antibodies and methods of use thereof
GB2595299B (en) 2020-05-21 2022-08-03 Mabsolve Ltd Modified immunoglobulin FC regions
TWI872251B (zh) 2020-05-29 2025-02-11 日商中外製藥股份有限公司 含有抗體製劑
EP4272756A4 (en) * 2021-02-05 2024-12-11 Bio-Thera Solutions, Ltd. ANTI-IL-5 ANTIBODY FORMULATION, MANUFACTURING METHOD AND USE THEREOF
JP2024535831A (ja) 2021-09-15 2024-10-02 デルミラ・インコーポレイテッド 結節性痒疹の治療のためのｉｌ－１３阻害剤
AU2024217729A1 (en) 2023-02-08 2025-08-21 Immunos Therapeutics Ag FUSION PROTEINS OF ß2 MICROGLOBULIN, HLA HEAVY CHAIN POLYPEPTIDES, AND INHIBITOR OF CD47-SIRPA
TW202544035A (zh) 2023-12-14 2025-11-16 美商德米拉股份有限公司 用於治療全年性過敏性鼻炎之il-13抗體
WO2025128984A1 (en) 2023-12-14 2025-06-19 Dermira, Inc. Il-13 antibodies for the treatment of chronic rhinosinusitis with nasal polyps
TW202600591A (zh) 2024-03-01 2026-01-01 美商德米拉股份有限公司 用於治療發炎後皮膚色素過多或色素過少之ｉｌ—１３抗體

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
CA2226575C (en) * 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
EP0999853B1 (en) * 1997-06-13 2003-01-02 Genentech, Inc. Stabilized antibody formulation
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
JP4340062B2 (ja) * 2000-10-12 2009-10-07 ジェネンテック・インコーポレーテッド 粘度の減少した濃縮タンパク質製剤
AU2002324556A1 (en) * 2001-07-25 2003-02-17 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
US7682608B2 (en) * 2001-08-29 2010-03-23 Chugai Seiyaku Kabushiki Kaisha Stabilized preparations containing antibody
US20040248260A1 (en) * 2001-10-26 2004-12-09 Heavner George A. IL-13 mutein proteins, antibodies, compositions, methods and uses
US20040191243A1 (en) * 2002-12-13 2004-09-30 Bei Chen System and method for stabilizing antibodies with histidine
AU2004210679A1 (en) * 2003-02-10 2004-08-26 Elan Pharmaceuticals, Inc. Immunoglobulin formulation and method of preparation thereof
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
US20070048785A1 (en) * 2004-06-09 2007-03-01 Lin Laura L Anti-IL-13 antibodies and complexes
PL1942939T5 (pl) * 2005-09-30 2021-10-11 Medimmune Limited Kompozycja przeciwciała interleukiny-13
KR20080071192A (ko) * 2005-11-22 2008-08-01 와이어쓰 면역글로불린 융합 단백질 제형
TW200806317A (en) * 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI476004B (zh) * 2009-03-11 2015-03-11 優稀美製藥股份有限公司 對人類ｉｌ－１３具結合專一性的抗體分子

Also Published As

Publication number Publication date
WO2008086395A2 (en) 2008-07-17
AR064826A1 (es) 2009-04-29
JP2010515742A (ja) 2010-05-13
CA2674608A1 (en) 2008-07-17
US20090060906A1 (en) 2009-03-05
BRPI0806313A2 (pt) 2011-09-06
WO2008086395A3 (en) 2008-10-16
MX2009007406A (es) 2010-01-25
CL2008000058A1 (es) 2008-05-23
CN101600457B (zh) 2014-01-08
EP2114451A2 (en) 2009-11-11
JP5419709B2 (ja) 2014-02-19
CN101600457A (zh) 2009-12-09
AU2008204901A1 (en) 2008-07-17
PE20081610A1 (es) 2008-12-09

Similar Documents

Publication Publication Date Title
JP5419709B2 (ja) 抗ｉｌ−１３抗体製剤およびその使用
JP6921148B2 (ja) 抗体製剤
JP7079844B2 (ja) 高濃度抗ｃ５抗体製剤
EP2991678B1 (en) Anti-il-4/anti-il-13 bispecific antibody formulations
RU2763787C2 (ru) Стабильные водные составы на основе антител
KR102004585B1 (ko) 조작된 항-IL-23p19 항체의 용액 제제
JP2010533181A (ja) ＴＮＦα阻害剤の肺投与のための方法及び組成物
RS61763B1 (sr) Antitela koja vezuju timusni stromalni limfopoetin (tslp) i metode za korišćenje antitela
ES3017790T3 (en) Dry powder formulations of thymic stromal lymphopoietin (tslp)-binding antibodies and methods of use thereof
CN102131827A (zh) 用于肺部传递给药的组合物
TWI764097B (zh) 包含抗ｃｄ４７抗體的製劑及其製備方法和用途
AU2011214299A1 (en) Methods and compositions for the preparation of aerosols
TW202200203A (zh) 包含抗IL-23p19抗體的製劑、其製備方法和用途
AU2014201308A1 (en) Anti-IL-13 antibody formulations and uses thereof
HK40000750A (en) Antibody formulations
HK40107164A (zh) Csf-1r抗体制剂
KR20230026407A (ko) 액티빈 a 항체 제형 및 이의 사용 방법
HK1215389B (en) Anti-il-4/anti-il-13 bispecific antibody formulations